Insulin Degludec, Recombinant

Modality

Insulin Degludec, Recombinant

Description of Insulin Degludec, Recombinant

Insulin degludec, chemically named LysB29(Nε-hexadecandioyl-γ-Glu) des(B30) human insulin analog, is a long-acting basal human insulin. Compared to human insulin, one amino acid at position B30 (ThrB30) of insulin degludec is deleted, and position 29 is linked to a side chain comprising glutamic acid and a C16 fatty acid.

Insulin degludec was developed by Novo Nordisk, and approved in 2015, with the brand name Tresiba, for glycemic control in diabetes mellitus patients.

Synonyms

IDeg, Insulin degludec (genetical recombination), Insulin degludec (USAN/INN), INSULIN-454, NN1250, SIBA, Soluble insulin basal analogue, Tresiba, Tresiba Flex Touch, Tresiba Penfill, 诺和达, トレシーバ

Amino Acid Sequence of Insulin Degludec

Insulin degludec differs from native human insulin at two amino acids of the B chain: B30 omitted and B29 chemically linked to a side chain.

Fig 1. Structure formula of insulin degludec

Expression System of Insulin Degludec

Typical Products	Active Substance	Expression System
Tresiba	Insulin degludec	Yeast (Saccharomyces cerevisiae)

Formulation of Insulin Degludec

Inactive Ingredients (Excipients) in Tresiba (Vial, Prefilled Pen/Cartridge)

Glycerin, metacresol, phenol, zinc, and hydrochloric acid or sodium hydroxide (pH 7.6)

All Categories

Insulin Degludec, Recombinant

Modality